Thrombin

LY135305 is a selective thrombin inhibitor that impedes thrombin activation. This compound demonstrates significant anti-metastatic properties, reducing spontaneous metastasis and contributing to improved survival rates in animal models. It is utilized in research focused on thrombin-related pathways and cancer metastasis.

(21S)-Argatroban is a specific thrombin inhibitor known for its anticoagulant properties. By interfering with thrombin activity, it effectively prolongs blood clotting time, while also reducing platelet adhesion and aggregation. This compound is useful in research applications aimed at understanding coagulation disorders and developing therapeutic strategies for thrombotic diseases.

Ro 09-1679 is a potent thrombin inhibitor with an IC50 of 33.6 μM, demonstrating significant inhibition of thrombin activity. Additionally, it effectively inhibits factor Xa, trypsin, and papain, with IC50 values of 3.3 μM, 0.04 μM, and 0.0346 μM, respectively. This compound is valuable for research applications focused on coagulation pathways, providing insights into thrombin's role in hemostasis and potential therapeutic interventions.

NAPAP is a selective direct thrombin inhibitor that binds rapidly to thrombin, effectively inhibiting its enzymatic activity. This compound demonstrates significant potential in reducing lipopolysaccharide (LPS)-induced neuroinflammation and expression of coagulation factors in vivo. NAPAP is valuable for research applications focused on coagulation pathways and neuroinflammatory processes.

LK-732 is a selective thrombin inhibitor that demonstrates significant anti-thrombotic activity. It exhibits dose-dependent inhibition of hypercoagulability, with an IC50 of 1.3 mg/kg. This compound is suitable for use in cardiovascular and cerebrovascular research applications, providing insights into thrombotic disorders and potential therapeutic interventions.

DuP 714 is a potent oral thrombin inhibitor that effectively inhibits thrombin-induced platelet aggregation with an IC50 value of 150 nM. This compound is valuable for research into arterial thrombosis, allowing for the investigation of thrombin's role in platelet activation and clot formation. Its selective mechanism makes it a crucial tool for studies aimed at understanding cardiovascular diseases and developing therapeutic strategies.

LY 806303 is a selective inhibitor of human α-thrombin, functioning primarily through the acylation of Ser-205 within the enzyme's catalytic triad. This modification disrupts the enzymatic activity of thrombin, delineating its role in various coagulation processes. LY 806303 is valuable for research applications focused on thrombin's involvement in hemostasis and thrombosis, providing insights into therapeutic strategies for related diseases.

RWJ-671818 is a potent oral inhibitor of human α-thrombin, exhibiting a Ki of 1.3 nM. This compound is particularly relevant in the study of venous and arterial thrombosis, providing insights into thrombotic mechanisms and potential therapeutic interventions. Its specificity for α-thrombin makes it a valuable tool in anticoagulant research.

BMS-189664 hydrochloride is a potent and selective reversible inhibitor of alpha-thrombin, exhibiting an IC50 value of 0.046 μM. This compound demonstrates significant anti-thrombotic activity and is suitable for research applications related to arterial and venous thrombosis. Its oral bioavailability makes it a valuable tool for in vivo studies of thrombotic disorders.

BMS-189664 is a selective and reversible inhibitor of α-thrombin, exhibiting a potent IC50 of 0.046 μM. This compound is valuable for investigating mechanisms involved in arterial and venous thrombosis. Its orally active nature facilitates its use in preclinical studies aimed at understanding thrombotic disorders and potential therapeutic interventions.

Napsagatran hydrate is a potent thrombin inhibitor that effectively antagonizes thrombin activity. It demonstrates significant anticoagulant effects both in vitro and in vivo, making it a valuable reagent for antithrombotic research. This compound is suitable for studies focused on coagulation and related pathways, contributing to the development of therapeutics for thrombotic disorders.

Atecegatran is an orally active competitive thrombin inhibitor targeting thrombin with a Ki value of 2-4 nM. By blocking thrombin's interaction with fibrin and thrombomodulin, it effectively inhibits platelet activation and aggregation. Demonstrating significant anticoagulant properties, Atecegatran exhibits an IC50 range of 93 to 220 nM in various plasma coagulation assays. This reagent is valuable for research focused on thromboembolic disorders and related cardiovascular studies.

Flovagatran sodium is a potent and reversible thrombin inhibitor with a Ki of 9 nM. This compound demonstrates significant efficacy in studies related to arterial and venous thrombosis, making it a valuable tool for hematological research. Its ability to selectively target thrombin enhances its utility in elucidating mechanisms of coagulation and developing therapeutic strategies for thrombotic disorders.

Pirmagrel is a thrombin synthetase inhibitor that effectively reduces thrombin secretion stimulated by lipopolysaccharide. Its primary mechanism involves the inhibition of thrombin synthesis, making it a valuable tool for studies related to coagulation and inflammation. This reagent is applicable in research focusing on thrombotic disorders and assessing the biological pathways influenced by thrombin regulation.

LB30057 (CI-1028) is a selective thrombin inhibitor with an inhibitory concentration (IC50) of 0.38 nM for human thrombin. This orally active compound is suitable for research on thrombus formation and related cardiovascular studies, making it a valuable tool for investigations into coagulation disorders and antithrombotic therapies.

Thrombin inhibitor 1 is a potent thrombin inhibitor with a Ki value of 0.66 nM and a 2xaPTT of 0.43 μM. This compound effectively inhibits thrombin activity, making it a valuable tool for studying blood coagulation and developing anticoagulant therapies. Its high specificity and efficacy render it suitable for various research applications in cardiovascular and hemostasis studies.

PPACK TFA is a potent and selective irreversible inhibitor of thrombin, demonstrating significant anticoagulant properties. It serves as an alternative to lithium heparin for blood gas and whole blood electrolyte analyses. Additionally, PPACK TFA inhibits plasminogen activator (rt-PA), interfering with its binding to plasma protease inhibitors, and mitigates plasmin-induced alterations in endothelial permeability and morphology in bovine aortic endothelial cell monolayers. This compound is valuable for investigations related to thrombosis and endothelial function.

PPACK dihydrochloride is a potent and selective irreversible inhibitor of thrombin. It serves as an alternative anticoagulant to lithium heparin for blood gas and electrolyte analyses in whole blood. Additionally, PPACK dihydrochloride inhibits plasminogen activator (rt-PA), preventing its binding to plasma protease inhibitors. This compound also reduces plasmin-induced endothelial permeability and morphological changes in bovine aortic endothelial cell monolayers, making it suitable for investigations in thrombosis-related research.

Argatroban monohydrate is a direct and selective inhibitor of thrombin. It plays a critical role in anticoagulation therapy, particularly for patients with heparin-induced thrombocytopenia. Argatroban is widely used in research to study coagulation pathways and evaluate potential therapeutic approaches for thrombotic disorders.